listened Comprehensive Study Guide for Bone Health: Osteopenia and Osteoporosis

Bone Health Overview and Scope of the Problem\n\n* Epidemiology and Statistics (US Populated Estimates):\n * Approximately $10.2 – 12.3 \text{ million}$ Americans are affected by osteoporosis.\n * Incidence of fractures: Approximately $2 \text{ million}$ annual fractures are attributed to osteoporosis. This figure exceeds the combined new cases of myocardial infarction (MI), breast cancer, and prostate cancer.\n * Projections: The number of fractures is expected to rise to $3.2 \text{ million}$ per year by $2040$.\n\n* Clinical Consequences of Fractures:\n * Hip Fractures: Associated with a one-year mortality rate ranging from $8.4\% \text{ to } 36\%$. Approximately $20\%$ of hip fracture patients require long-term nursing home care. Only $40\%$ of patients return to their pre-fracture level of independence.\n * Vertebral Fractures: These can be symptomatic or \u201csilent.\u201d They serve as a robust predictor for future risk, indicating a $5\text{-fold}$ increase in subsequent vertebral fractures and a $2\text{-3 fold}$ increase in other fracture types.\n\n* Historical Trends: Data from Lewiecki ($2017$) shows age-adjusted incidence of hip fractures in the US measured per $100,000$ people. While there was a decline between $2001$ and $2012$, joinpoint regression and projections are monitoring future trends for the aging population.\n\n# Medication Experience and Patient Perspectives\n\n* Case Study: 71-Year-Old Female:\n * Diagnosis: Recently found to have vertebral fractures on Vertebral Fracture Assessment (VFA) with a history of osteoporosis treatment.\n * Adverse Reaction History:\n * Bisphosphonates: Reported \u201chorrible joint & muscle pains\u201d described as having a \u201ccrippling effect.\u201d\n * Raloxifene: Reported memory loss and \u201cpoor thinking.\u201d Retrial resulted in the patient \u201cfeeling awful\u201d and \u201cworking through a cloud.\u201d\n * Patient Attitude: \u201cI don’t want to take medications for my osteoporosis.\u201d\n\n* Common Patient Themes and Barriers to Treatment:\n * Denial of Risk: \u201cI just can’t believe I have osteoporosis. I drank milk my whole life, and I’ve always been physically fit.\u201d\n * Fear of Adverse Effects: Patients express fear of cancer, skin infections, or osteonecrosis of the jaw (\u201cruining my jaw\u201d), opting to \u201ctake their chances\u201d with fractures instead.\n * Skepticism of Efficacy: Concerns that medications build \u201cpoor bone\u201d and may actually cause fractures.\n\n# Bone Health Risk Factors\n\n* Lifestyle Factors:\n * Alcohol abuse (excessive consumption).\n * Excessive thinness and low body weight.\n * Excessive intake of Vitamin A.\n * Frequent falling.\n * High salt intake.\n * Immobilization or inadequate physical activity.\n * Low calcium intake and Vitamin D insufficiency.\n * Smoking (both active and passive exposure).\n\n* Race and Gender Variations:\n * Females: Highest fracture risk in non-Hispanic white and Hispanic-American populations, followed by Native Americans, African Americans, and Asian Americans.\n * Males: Highest hip fracture incidence in non-Hispanic white men; similar rates among Hispanic-American and black men; lowest incidence in Asian men.\n\n* Medical Conditions Associated with Bone Loss:\n * Genetic/Autoimmune: Cystic Fibrosis (CF), Rheumatoid arthritis, Multiple Sclerosis (MS).\n * Endocrine/Hypogonadal: Cushing’s Syndrome, Hyperparathyroidism, Thyrotoxicosis, Diabetes (Type $1$ and Type $2$), hypogonadal states.\n * Gastrointestinal: Celiac disease, Inflammatory Bowel Disease (IBD), Gastric bypass/bariatric surgery, malabsorption syndromes.\n * Neurological: Epilepsy, Parkinson's disease.\n * Other: Obesity, End-stage kidney disease, Post-transplant bone disease, Parental history of hip fracture.\n\n* Fall and Fracture Risk Factors:\n * Biological: Advanced age, female sex, arthritis, orthostatic hypotension, poor vision or hearing, frailty, sarcopenia, proximal myopathy.\n * Neurologic Disorders: Seizure disorders, peripheral neuropathy, prior stroke, dementia, gait/balance impairment, autonomic dysfunction.\n * Environmental Factors: Poor lighting, slippery or icy floors, uneven pavement, throw rugs, loose wires/cords, presence of large dogs or small dogs that may trip the patient.\n * Generic Clinical Factors: Previous falls and urinary urgency/incontinence.\n\n* Medications Inducing Bone Loss:\n * Aluminum-containing antacids.\n * Androgen deprivation therapy (ADT).\n * Anticoagulants (specifically Unfractionated Heparin - UFH).\n * Anticonvulsants (Phenobarbital, Phenytoin, Valproate).\n * Aromatase inhibitors (AI).\n * Barbiturates and Chemotherapy agents.\n * Cyclosporine and Tacrolimus.\n * Glucocorticoids (specifically Prednisone doses > 5\,mg/\text{day} for > 3\,months).\n * GnRH agonists and antagonists, and Depo-MPA.\n * Methotrexate, Proton Pump Inhibitors (PPIs), SSRIs, TZDs.\n * Tamoxifen (premenopausal use only).\n * Parenteral nutrition and excess thyroid hormone.\n\n# Assessing Bone Health and Diagnostic Criteria\n\n* Dual-energy X-ray Absorptiometry (DXA):\n * The gold standard for assessment, typically measuring the lumbar spine and hip.\n * Bone Mineral Density (BMD) is expressed in $g/cm^2$.\n * Z-score: BMD compared to an age-, sex-, and ethnicity-matched reference population.\n * T-score: BMD compared to a young-adult reference population of the same sex.\n\n* WHO Classification (Based on BMD T-score):\n * Normal: $T ≥ -1.0$.\n * Low Bone Mass (Osteopenia): Between $-1.0$ and $-2.5$.\n * Osteoporosis: $T ≤ -2.5$.\n\n* Clinical Criteria for Osteoporosis Diagnosis (Men and Women > 50):\n * Presence of an incident fragility fracture (hip, vertebral, or forearm) regardless of BMD.\n * T-score between $-1.0$ and $-2.5$ accompanied by a FRAX-projected $10\text{-year}$ risk of $\ge 3\%$ for hip fracture or $\ge 20\%$ for major osteoporosis-related fracture.\n\n* AACE/ACE Diagnostic Additions:\n * Osteoporosis can be diagnosed based on T-score of $-2.5$ or lower in the lumbar spine, femoral neck, total hip, or $1/3$ radius ($33\%$ radius).\n * Diagnosis is lifelong: even if a subsequent DXA shows an improved T-score better than $-2.5$, the diagnosis of osteoporosis persists for management purposes.\n\n# Screening Recommendations\n\n* BHOF Guidelines (KNOW THESE):\n * Women aged $\ge 65$.\n * Men aged $\ge 70$.\n * Younger postmenopausal women or men aged $50\text{--}69$ with clinical risk factors.\n * Adults > 50 with a history of adult-age fracture.\n\n* USPSTF Recommendations ($2025$ Update):\n * Screen all women $\ge 65$.\n * Screen women < 65 at increased risk as determined by clinical risk assessment tools.\n * Evidence is insufficient to assess screening in men.\n\n* NAMS Screening Recommendations:\n * Measure density in postmenopausal women when it will influence management, specifically including those with history of fracture since menopause, known medical causes of loss, or age $\ge 65$.\n * Screen age $50+$ if they have: weight < 127\,lb ($57.7\,kg$), BMI < 21\,kg/m^2, parental hip fracture, smoking, discontinuation of estrogen, excess alcohol, or long-term high-risk medication use.\n\n* Vertebral Fracture Imaging (BHOF/NAMS Criteria):\n * Women $\ge 65$ if $T ≤ -1.0$ at the femoral neck.\n * Women $\ge 70$ and men $\ge 80$ if $T ≤ -1.0$ at the lumbar spine, total hip, or femoral neck.\n * Men $70\text{--}79$ if $T ≤ -1.5$ at the lumbar spine, total hip, or femoral neck.\n * Adults $\ge 50$ with: adulthood fracture, historical height loss $\ge 1.5\,in$, prospective height loss $\ge 0.8\,in$, long-term glucocorticoid use, or hyperparathyroidism.\n\n# FRAX (Fracture Risk Assessment Tool)\n\n* Functionality: A statistical model designed for patients aged $40\text{--}90$ to calculate the $10\text{-year}$ probability of fracture.\n* Required Inputs:\n * Current age, gender, BMI ($kg/m^2$).\n * Prior osteoporotic fracture (spontaneous or low-trauma fracture in adult life).\n * Parental history of hip fracture.\n * Current smoking and alcohol intake ($3$ or more drinks per day).\n * Oral Glucocorticoids (Prednisolone > 5\,mg/\text{day} for > 3\,months, ever).\n * Rheumatoid arthritis and Secondary causes (Type $1$ DM, long-standing hyperthyroidism, chronic malabsorption, etc.).\n * Femoral neck BMD ($g/cm^2$ or T-score).\n\n# Nonpharmacologic and Lifestyle Management\n\n* Physical Activity: Emphasize weight-bearing and resistance exercises.\n* Lifestyle Cessation: Smoking cessation and limiting alcohol consumption ($1$ drink/day for women, $2$ for men).\n* Fall Prevention Checklist:\n * Anchor rugs and remove loose wires/cords.\n * Minimize clutter and install handrails in bathrooms and hallways.\n * Ensure proper lighting in stairwells and entrances.\n * Wear sturdy, low-heeled shoes; use nonskid mats.\n * Consult Beer's List and STOPP criteria for high-risk medications.\n\n# Calcium and Vitamin D Supplementation\n\n* Recommended Daily Intake (IOM/NOF):\n * Ages 19-50: Calcium $1000\,mg$, Vitamin D $400\text{--}600\,units$.\n * Men 50-70: Calcium $1000\,mg$, Vitamin D $800\text{--}1000\,units$.\n * Women > 51 / Men > 71: Calcium $1200\,mg$, Vitamin D $800\text{--}1000\,units$.\n\n* Guidelines on Bone and Cardiovascular (CV) Health:\n * ACP (2017): Moderate quality evidence shows no association between calcium and adverse CV outcomes, but fracture impact is uncertain due to low adherence.\n * BHOF (2022): Adequacy of calcium is lifelong; litearture on CVD is conflicting but meta-analyses show no evidence of increased risk.\n * ICSI (2017): Preference for dietary calcium; supplements should only fill the gap.\n\n* Calcium Formulations:\n * Calcium Carbonate: Requires an acidic environment (take with food); may have poor absorption with PPI use; more associated with constipation (e.g., Caltrate, Os-Cal).\n * Calcium Citrate: Does not require acid; better tolerated and suitable for patients on PPIs (e.g., Citracal).\n * Absorption Rule: Regardless of formulation, absorption is limited; do not exceed $500\text{--}600\,mg$ per individual dose.\n\n* Estimating Dietary Intake Formula:\n * Step 1: Calculate calcium-rich foods (Milk $8\,oz = 300\,mg$; Almond/Soy milk $8\,oz = 450\,mg$; Yogurt $6\,oz = 300\,mg$; Cheese $1\,oz = 200\,mg$; Tofu $8\,oz = 250\,mg$).\n * Step 2: Add $250\,mg$ for non-dairy sources.\n\n# Pharmacological Treatments\n\n* Classifications:\n * Antiresorptive: Lower bone turnover. Includes Bisphosphonates, Denosumab, Calcitonin.\n * Anabolic: Increase bone formation. Includes Teriparatide, Abaloparatide, Romosozumab (dual action).\n * Estrogen Agonists: Estrogen products, Raloxifene, CEE/Bazedoxifene.\n\n* AACE/ACE Treatment Algorithm:\n * High Risk (no prior fractures): Initial options are Alendronate, Denosumab, Risedronate, or Zoledronate. Alternates: Ibandronate, Raloxifene.\n * Very High Risk (prior fractures, very low T-score < -3.0, or FRAX > 30% major/4.5% hip): Initial options include Abaloparatide, Denosumab, Romosozumab, Teriparatide, or Zoledronate.\n * Drug Holidays: Consider after $5\,years$ of oral or $3\,years$ of IV bisphosphonates if BMD is stable.\n\n* Efficacy Comparison (NNT to prevent 1 fracture over 3 years):\n * Alendronate: NNT $15$ (Vertebral), $91$ (Hip).\n * Zoledronic Acid: NNT $14$ (Vertebral), $91$ (Hip).\n * Denosumab: NNT $21$ (Vertebral), $200$ (Hip).\n * Teriparatide: NNT $11$ (Vertebral over $19\,months$).\n * Romosozumab: NNT $77$ (Vertebral over $1\,year$); dramatically improves if followed by alendronate/denosumab.\n\n* BMD Increases (Lumbar Spine - LS):\n * Denosumab: Max increase of $21.7\%$ over $10\,years$.\n * Romosozumab: $13.3\%$ over $1\,year$.\n * Teriparatide: $9.5\%$ over $18\text{--}19\,months$.\n * Bisphosphonates: Plateau after approximately $5\,years$ with increases around $3\text{--}6\%$.